Axsome Therapeutics Q2 2025: $150M Revenue, Expanding Pipeline

Axsome Therapeutics soars in Q2 2025 with $150M revenue, up 72% YoY and 24% QoQ, driven by Auvelitys 84% YoY surge and Sunosis 35% QoQ growth. New migraine drug SYMBRAVO launches, netting $410K in partial quarter. Sales force expands, payer coverage improves, with Auvelity prescriptions up 15% QoQ. Early feedback on SYMBRAVO is positive. Pipeline includes sNDA for AXS-zero-five in Alzheimers agitation, AXS-twelve NDA for narcolepsy, and solriamfetol trials in ADHD, binge eating, and more. Despite net loss of $48M, Axsome ends with $303M cash, poised for profitability. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/90289931aeb64910